BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luca T, Barresi V, Privitera G, Musso N, Caruso M, Condorelli DF, Castorina S. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif 2014;47:435-47. [PMID: 25131935 DOI: 10.1111/cpr.12125] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Chai EZP, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, Samy RP, Lim LH, Wang L, Goh BC, Ahn KS, Hui KM, Sethi G. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacology & Therapeutics 2016;162:86-97. [DOI: 10.1016/j.pharmthera.2015.10.004] [Cited by in Crossref: 161] [Cited by in F6Publishing: 168] [Article Influence: 26.8] [Reference Citation Analysis]
2 Takegawa N, Yonesaka K. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. Clinical Colorectal Cancer 2017;16:247-51. [DOI: 10.1016/j.clcc.2017.03.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
3 Gomes SE, Simões AE, Pereira DM, Castro RE, Rodrigues CM, Borralho PM. miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget 2016;7:9368-87. [PMID: 26824186 DOI: 10.18632/oncotarget.7010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
4 Yar Saglam AS, Alp E, Elmazoglu Z, Menevse S. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. Hum Exp Toxicol 2016;35:526-43. [PMID: 26183715 DOI: 10.1177/0960327115595686] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
5 Chang H, Zou Z. Targeting autophagy to overcome drug resistance: further developments. J Hematol Oncol 2020;13:159. [PMID: 33239065 DOI: 10.1186/s13045-020-01000-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
6 Luca T, Napoli E, Privitera G, Musso N, Ruberto G, Castorina S. Antiproliferative Effect and Cell Cycle Alterations Induced by Salvia officinalis Essential Oil and Its Three Main Components in Human Colon Cancer Cell Lines. Chem Biodivers 2020;17:e2000309. [PMID: 32531144 DOI: 10.1002/cbdv.202000309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Int J Mol Sci 2021;22:6813. [PMID: 34202896 DOI: 10.3390/ijms22136813] [Reference Citation Analysis]
8 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
9 Chen Z, Wang T, Tu X, Xie W, He H, Wang M, Zhang J. Antibody-based targeting of CD24 enhances antitumor effect of cetuximab via attenuating phosphorylation of Src/STAT3. Biomed Pharmacother. 2017;90:427-436. [PMID: 28391164 DOI: 10.1016/j.biopha.2017.03.094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Chen Z, Xie W, Acheampong DO, Xu M, He H, Yang M, Li C, Luo C, Wang M, Zhang J. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity. Cancer Biol Ther 2016;17:139-50. [PMID: 26671532 DOI: 10.1080/15384047.2015.1121344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Hasbal-Celikok G, Aksoy-Sagirli P, Altiparmak-Ulbegi G, Can A. Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. Oncol Lett 2021;21:209. [PMID: 33574948 DOI: 10.3892/ol.2021.12470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res 2021;40:328. [PMID: 34663410 DOI: 10.1186/s13046-021-02130-2] [Reference Citation Analysis]
13 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22. [PMID: 32296018 DOI: 10.1038/s41392-020-0116-z] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 65.0] [Reference Citation Analysis]
14 Accardo A, Del Zoppo L, Morelli G, Condorelli DF, Barresi V, Musso N, Spampinato G, Bellia F, Tabbì G, Rizzarelli E. Liposome antibody–ionophore conjugate antiproliferative activity increases by cellular metallostasis alteration. Med Chem Commun 2016;7:2364-7. [DOI: 10.1039/c6md00461j] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]